The FDA approval of Opdivo Qvantig (nivolumab and hyaluronidase-nvhy ... and Priority Review status and assigned the sBLA a target action date of June 23, 2025. Approval of New Drugs is Imperative ...

CEL-SCI (CVM) announced that a third-party study published on March 6 in JAMA Oncology provided data that support Multikine’s use as a ...

Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of Head and Neck Patients.

They will receive two cycles of nivolumab combined with AVD therapy ... or refraining from, any action on the basis of the content on our site.